P583 Outcome of treat to target strategy in paediatric patients with Crohn’s disease and ulcerative colitis on adalimumab
D. Yerlioglu*1, L. Cococcioni1, A. ElZein1, S. Chadokufa1, R. Buckingham1, S. Sider1, N. Shah1, A. Ocholi1, O. Borrelli1, F. Kiparissi1
1Great Ormond Street Hospital, Gastroenterology, London, UK
Treat to target strategy has been proposed in adult IBD to improve Quality of Life, symptoms and to treat inflammation. There are little data in the paediatric population for this approach. The aim of this study was to look if set goals (reduced PCDAI/PUCAI and Mayo/SES-CD) were achieved.
We conducted a retrospective analysis of children with IBD who received Adalimumab (ADA) in our institution. Data were collected to evaluate mucosal healing for UC from colonoscopy results, using Mayo Scoring and for CD using SES-CD. We also compared These data with activity scores (PUCAI and PCDAI), CRP and Faecal Calprotectin, (FC).
A total of 24 patients were identified, 20 (Group 1) with Crohn’s disease (CD), 4 (Group 2) with ulcerative colitis (UC); Male
CRP precommencing median (
This study suggests that setting a target and monitoring SES-CD in CD and Mayo scoring in UC improves clinical outcomes (PCDAI and PUCAI), more in Crohn’s disease than Ulcerative colitis. Treat to target should become routine clinical management in paediatric IBD patients.